Short name: B22956, generic name: Gadocoletic acid, chemical compound: Gadocoletic acid trisodium salt, central moiety: Gd, phase: II
A blood pool agent for magnetic resonance coronary angiography and first pass myocardial perfusion imaging under development (Bracco Diagnostics Inc). The small molecules of gadolinium-based B22956 are bound after injection to large human serum albumin molecules in coronary vessels with the result of high vessel/muscle contrast.

The company is a member of the Bracco Group, a highly innovative healthcare group and world leader in global integrated solutions for the diagnostic medical imaging field. The Bracco Group is headquartered in Milan, Italy. Its North American operations consist of Bracco Diagnostics and Bracco Research USA, both located in Princeton, New Jersey. Bracco Diagnostics is one of the fastest growing developers and marketers of diagnostic pharmaceuticals in North America, with products for various imaging applications, including Isovue® (iopamidol - X-ray contrast agent), ProHance® (gadoteridol - MRI contrast agent), SonoVue® (ultrasound contrast agent) and nuclear medicine products.
Gadoteridol has been available in Europe and the USA for several years. Holder of the Marketing Authorization: Bracco International B.V. - Strawinskylaan 3051 - 1077 ZX Amsterdam The Netherlands. (Contact: Kirk Deeter, Phone: +NL-303-838-8708)

MRI Contrast Agents: